Sam Brusco, Associate Editor10.03.23
Delphinus Medical Technologies, a medical imaging company, has promoted Scott A. White to be its new president and CEO. White is the company’s former chief commercial officer (CCO) and replaces retiring president and CEO Mark J. Forchette, who will remain with the company as an advisor and member of the board.
White was brought on as Delphinus’ CCO in February 2023. He has over 25 years’ experience in commercial, operations, and finance leadership.
Before joining Delphinus, White was CCO of Hyperfine, developer of a bedside neurological MRI platform. He previously served as VP of global sales at Rapid Micro Biosystems, and was area VP at Intuitive Surgical for eight years.
Delphinus’ SoftView 3D whole breast tomography system screens dense breasts and achieved U.S. Food and Drug Administration (FDA) approval in October 2021. The company said that when paired with mammography, SoftVue was shown to identify up to 20% more cancers, reduce false positives, and decrease unnecessary call-backs and biopsies in women with dense breasts.
Former president and CEO Forchette told the press, “My experience as president and CEO of Delphinus has been immensely rewarding. I have had the opportunity to lead an amazing team, deliver a breakthrough technology to benefit patients, earn a PMA for dense breast screening and save lives through commercial implementation. I’m so proud of our work and truly appreciate the opportunity I’ve had to serve as CEO. Scott is a proven leader and shares my passion that SoftVue is the solution to address the unmet needs of dense breast screening patients. The board and I are confident that he will lead the company into a very successful future.”
“I’m incredibly thankful for the opportunity to lead the Delphinus team into the future,” White added. “The Delphinus SoftVue system is unlike any other technology in the market today, and we believe it is the answer to the dense breast screening challenge that currently exists for tens of millions of women.” White went on to say, “I’m honored by the support both Mark and the board have provided me in accepting this new position.”
White was brought on as Delphinus’ CCO in February 2023. He has over 25 years’ experience in commercial, operations, and finance leadership.
Before joining Delphinus, White was CCO of Hyperfine, developer of a bedside neurological MRI platform. He previously served as VP of global sales at Rapid Micro Biosystems, and was area VP at Intuitive Surgical for eight years.
Delphinus’ SoftView 3D whole breast tomography system screens dense breasts and achieved U.S. Food and Drug Administration (FDA) approval in October 2021. The company said that when paired with mammography, SoftVue was shown to identify up to 20% more cancers, reduce false positives, and decrease unnecessary call-backs and biopsies in women with dense breasts.
Former president and CEO Forchette told the press, “My experience as president and CEO of Delphinus has been immensely rewarding. I have had the opportunity to lead an amazing team, deliver a breakthrough technology to benefit patients, earn a PMA for dense breast screening and save lives through commercial implementation. I’m so proud of our work and truly appreciate the opportunity I’ve had to serve as CEO. Scott is a proven leader and shares my passion that SoftVue is the solution to address the unmet needs of dense breast screening patients. The board and I are confident that he will lead the company into a very successful future.”
“I’m incredibly thankful for the opportunity to lead the Delphinus team into the future,” White added. “The Delphinus SoftVue system is unlike any other technology in the market today, and we believe it is the answer to the dense breast screening challenge that currently exists for tens of millions of women.” White went on to say, “I’m honored by the support both Mark and the board have provided me in accepting this new position.”